An NCI-designated Consortium Cancer Center
|
|
|
Weekly Research Newsletter
|
|
|
Now Recruiting: Moores Cancer Center (MCC) Clinical Trials Office (CTO) Co-Medical Directors
MCC and CTO are now seeking two candidates for the position of MCC CTO Co-Medical Director. Indeed, MCC and CTO have expanded the support for this essential role to now recruit two faculty leaders to provide oversight of cancer clinical trials. The leadership responsibilities will be shared equally by the two Co-Medical Directors; however, each will possess a different portfolio of duties and shared oversight at MCC and all locations where MCC clinical trials are conducted.
The principal role of the CTO Co-Medical Director is to direct overall CTO clinical strategies and operations to ensure safe, compliant, and efficient cancer clinical trial conduct. Together, the two Co-Medical Directors will report to the MCC Associate Director for Clinical Science and receive strategic guidance from the not only the MCC executive team, but also Health Sciences leadership.
Any faculty members interested in serving in this role are encouraged to submit (1) a letter of interest that includes your vision for the position and (2) a recent CV to Xochitl Villanueva at xvillanueva@health.ucsd.edu by Monday, March 13, 2023.
|
|
|
MCC Town Hall
At the first MCC Quarterly Town Hall that took place on February 13, 2023, the MCC draft strategic plan, MCC clinical volume and finance updates, and MCC Research Administration progress on delivering the best “researcher experience” possible were presented. This hybrid event, held in MCC Goldberg Auditorium and on Zoom, was attended by 300 participants. In the event that you missed it, below is the link and password to the recording of the presentations and Q&A segments.
https://uchealth.zoom.us/rec/share/myGjAaUhb6JmWD7xEXspVq53ItLt4vNqB5TrL6bPFGKHnFrSxI2h6la4itfUoA.dRK3OL9r1btXWo0s
Passcode: Townhall4!
Link expires March 14, 2023.
|
|
|
Soliciting Interest for the NCI PREVENT Program: Virtual Session with Dr. Mark Miller (NCI)
NCI PREVENT is a peer-reviewed program designed to support development of the best ideas in cancer prevention using NCI contract resources. The program is a pipeline that addresses unmet needs in prevention that are not adequately addressed by the private sector.
Dr. Mark Miller, Deputy Chief of Chemopreventive Agent Development Research Group and Director of PREVENT Operations, Division of Cancer Prevention, NCI, will be available to provide a 20-30 minute virtual presentation about the PREVENT Program to interested faculty.
If interested in attending Dr. Miller’s presentation, then send an email expressing your interest to Daniel Libraty, M.D., MCC Research Grant Writer at dlibraty@health.ucsd.edu by Wednesday, March 15, 2023.
|
|
|
Resuming In-Person Structural and Functional Genomics (SFG) Cross Lab Meetings, Starting April 12, 2023
Starting Wednesday April 12, 2023, in-person SFG Cross-Lab Meetings will resume. All in-person SFG Cross-Lab Meetings will be held in alternating locations (i.e., Leichtag, each 2nd Wednesday of the month; Comer Commons, each 4th Wednesday of the month) at 12:00 p.m.
SFG is excited for in-person interaction and looks forward to your participation. Lunch, light refreshments, and coffee will be served.
|
|
|
Join the MCC Work in Progress Seminar Series
Please join MCC's standing Work in Progress Seminar Series every first Wednesday of the month. If you are interested in presenting or joining, then please contact Program Coordinator, Diana Arroyo at d1arroyo@health.ucsd.edu.
|
|
|
Highlights from The Cancer Letter |
UNM’s Sanchez: To Provide Cancer Care to Native American, Hispanic Communities, You Must First Establish Trust
Read full article on page 6 of The Cancer Letter, volume 49 number 10.
Biden Requests $503M Increase for NCI, New Funds for the Moonshot, $1B for ARPA-H in FY24
Read full article on page 24 of The Cancer Letter, volume 49 number 10.
|
|
|
| DRM Seminar Series
Teaching New Tricks to an Old Thymus
Monday, March 13, 2023 from 3:00 to 4:00 p.m. PT
Sanford Consortium for Regenerative Medicine
Conference Room 1013 A/B
2880 Torrey Pines Scenic Drive
La Jolla, CA 92037
Zoom link: Available upon request
Juan Carlos Zuniga-Pflucker, Ph.D.
Professor and Chair, Department of Immunology
Senior Scientist, Sunnybrook Research Institute
University of Toronto
Hosted by Dan Kaufman, M.D., Ph.D.
|
|
|
|
Pharmacology Seminar Series
How Small Changes in Lipid Chemistry Shape Cellular Organelles Drive Their Dysfunction in Metabolic Disease
Tuesday, March 14, 2023 at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
UC San Diego, School of Medicine
Optional Webinar Registration
Itay Budin, Ph.D.
Assistant Professor
Department of Chemistry and Biochemistry
UC San Diego
Hosted by Susan Taylor, Ph.D.
|
|
|
|
Cancer Biology and Signaling Seminar Series
Regulating Energy Homeostasis
Wednesday, March 15, 2023 at 12:00 p.m. PT
MCC Comer Commons
Lunch Provided
Optional Webinar Registration
Alan Satiel, Ph.D.
Professor of Medicine and Pharmacology
UC San Diego
|
|
|
|
Cancer Cell and Tumor-Associated Macrophage Metabolism: Mechanisms and Pharmacological Modulation
Wednesday, March 22, 2023 at 12:00 p.m. PT
Biomedical Sciences Building (BSB)
Room 1105, Garren Auditorium
9500 Gilman Drive
La Jolla, CA 92161
Optional Webinar
Alexandra K. Kiemer, Ph.D.
Head of the Pharmaceutical Biology Group
Saarland University
|
|
|
| SFG Cross-Lab Meeting
Integration of Clinical and Translational Pipelines
Wednesday, March 22, 2023 at 12:00 p.m. PT
Zoom Link
Rana McKay, M.D.
Associate Professor of Medicine and Urology
UC San Diego, School of Medicine
Associate Director of Translational Sciences
Co-Leader, Genitourinary Oncology Program
UC San Diego, MCC
|
|
|
Student Volunteers Available for Spring Quarter, Beginning April 3, 2023
MCC Cancer Research, Training, Education, and Coordination (CRTEC) has identified a number of enthusiastic UC San Diego undergraduate students who are interested in volunteering in a lab at MCC. This is a win-win research experience for the students and your lab.
If you are interested in a student volunteer, then please complete the REDCap form below for CRTEC to match you with an appropriate student.
https://redcap.link/lebsyfcm
Students can begin volunteering at the beginning Spring Quarter 2023, which begins this year on Monday, April 3, 2023.
Please contact Amy Spilkin, Ph.D. at aspilkin@health.ucsd.edu with any questions that you may have about this opportunity.
|
|
|
Speed Mentoring Workshop, Faculty Sign Ups
Faculty Members of MCC are invited to serve a mentors at the MCC Speed Mentoring Workshops, organized by MCC CRTEC. These workshops serve not only undergraduate, graduate, and post-graduate students, but also project scientists, research scientists, and junior faculty. Please select the session(s) for which are are available to mentor, and please select all that apply. You will be scheduled for only one of the dates that you choose—providing several dates merely helps to coordinate schedules. You will be contacted with a confirmation of the schedule.
CRTEC Speed Mentoring takes place on the second Thursday of each month from 12:00 p.m. to 1:00 p.m. on Zoom. Participating faculty members will receive 1 hour of mentorship credit, approved by MCC leadership.
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITIES
|
|
|
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)
This award encourages career development for cancer clinical trial investigators who provide leadership, participation, and scientific support for NCI clinical trials networks at their institutions and within those networks.
The NCI invites applications for the Research Specialist Award in any area of NCI-funded clinical cancer research. Specifically, award is for clinician scientists to continue to participate in NCI clinical trials networks through leadership in (1) developing national clinical trials, (2) implementation of NCI clinical trials in their institutions, and (3) national service to the NCI clinical trials networks through participation in scientific review committees, monitoring committees, and other activities—not serving as principal investigators of research project grants.
Because these clinician scientists are vital to sustaining the NCI-funded clinical trials enterprise, the Research Specialist Award will provide stable support for clinician scientists at their institutions to contribute leadership in NCI-sponsored clinical trials networks that conduct cancer treatment, cancer prevention and control, and cancer care delivery clinical trials. NCI-sponsored clinical trials networks include but are not limited to the National Clinical Trials Network (NCTN), the NCI Community Oncology Research Program (NCORP), the Experimental Therapeutics Clinical Trials Network (ETCTN), and the Cancer Prevention Clinical Trials Network (CP-CTNet).
To be considered for nomination, please send a 1-page LOI to Divya Subramonian, Ph.D. at dsubramonian@health.ucsd.edu for review by our MCC grants committee. LOI instructions appear below.
All LOIs must be submitted to Divya Subramonian, Ph.D. at dsubramonian@health.ucsd.edu as a single PDF by the internal deadline of Monday, March 20, 2023 at 5:00 p.m. Please follow the instructions below:
|
-
Cover page must include your name, degree(s), complete academic title, department, phone number, email address; grant name; project title; and verification that all eligibility criteria are met.
- Letter of Intent / Research Statement (1 page maximum)
- Arial, at least 11-point font, at least 1/2-inch margins, 1 page maximum, including any figures or tables; citations only may be included on a second page.
- Briefly describe the research strategy per the FOA.
- NIH-style biosketch
- 5 pages max; include active and pending support.
-
Your LOI submission is NOT complete until you have received Acknowledgment of Receipt.
|
Deadline: Monday, March 20, 2023 at 5:00 p.m. PST
|
| |
SITC Fellowships: Funding Opportunities for Early Career Scientists
The Society for Immunotherapy of Cancer (SITC) is committed to assisting young investigators in advancing the science of immunotherapy. This year, the SITC Forward Fund is pleased to offer four SITC Fellowships, totaling $440,000 in funding. Get started on your application now! Submissions are due by March 27, 2023.
SITC Fellowships are only available to SITC members. Not a member? Sign up today.
Deadline: Monday, March 27, 2023
|
|
|
NIH Instrumentation Grant (S10) Programs: Institutional Coordination Required
Institutional coordination is required for all S10 requests. Investigators intending to submit an NIH shared instrumentation proposal for the June 2023 deadline must submit an internal LOI by the stated deadline to avoid potential overlap.
Applications received after the internal deadline are subject to review and may be confirmed to submit to the NIH only if the proposed instrument does not overlap with a proposal that was submitted by the internal deadline. The Office of Research Affairs will provide the mandatory institutional performance table for all applicants.
This internal call covers two companion NIH funding opportunities to support high-priced research instruments that (1) only can be justified on a shared-use basis and (2) are needed for NIH-supported projects in basic, translational, and clinical biomedical or bio-behavioral research. Programs provide funds to purchase or upgrade a single expensive, specialized, commercially available instrument or integrated system.
|
-
Under the Shared Instrumentation Grant (SIG) Program (PAR-22-080), the minimum award is $50,000. There is no maximum price limit for the instrument; however, the maximum award is $600,000.
-
Under the High-End Instrumentation (HEI) Grant Program (PAR-22-079), the minimum award is $600,001. There is no maximum price limit for the instrument; however, the maximum award is $2,000,000.
|
Eligibility/Requirements
Although the PD/PI need not have an NIH research grant or any other research support, he or she is expected to be an expert on the requested instrument. The PI may be a core director or tenured or non-tenured faculty member of the applicant organization. Multiple PIs are not allowed.
Applications must identify at least three "major users" who exhibit a "substantial need" for the instrument. Each of these users must be a PI on a distinct active NIH research award in an area of basic, translational, or clinical research. NIH training or fellowship grants, other non-research and SBIR/STTR grants, or other transaction (OT) awards and contracts cannot be counted toward the fulfillment of this requirement.
Resources
For complete details, please view the individual announcements for the Shared Instrumentation Grant and the High-End Instrumentation Grant. Applicants are advised to discuss with the relevant Scientific/Research Contact any questions about appropriate types of equipment, eligibility, and program requirements.
A list of recent awards and FAQs can be viewed on the S10 website.
Resources for preparing instrumentation grants, including a list of recurring funding opportunities that support equipment purchases, can be found on the internal Research Development website (SSO login required with @ucsd.edu form of campus credentials).
|
- Internal submission deadline: Tuesday, March 28, 2023 at 5:00 p.m.
- Funding organization deadline: Thursday, June 1, 2023
- Project Period: 1 year
-
Program website: https://orip.nih.gov/construction-and-instruments/s10-instrumentation-programs
- Sponsor reference number: PAR-22-079; PAR-22-080
- Cost-share or match required: No
- Amount note: Budgets vary by program
- Funding organization: NIH (ORIP, NIGMS, NIMH)
|
If you plan to apply for either the Shared or High-End Instrumentation Grant Program (S10), please submit the following information via ucsd.infoready4.com by the internal deadline:
|
- Instrument model. Provide the exact name of the requested instrument, including manufacturer and model.
-
Location. Provide the name of the building and core facility in which the instrument will be placed.
-
Brief justification. Why is this instrument needed at UC San Diego? If similar instrumentation is available on campus, then why it is not accessible to the requesting team? (3-5 sentences)
- Users. Which departments or areas of campus will the instrument serve? Include the names of three required and confirmed Major Users. (2-3 sentences)
|
Deadline: Tuesday, March 28, 2023 at 5:00 p.m.
Questions? Contact Lynsey Fitzpatrick (email)
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
2023 AIM-HI Women's Venture Competition
The AIM-HI Women's Venture Competition, now in its fourth year, is open to women-led oncology companies worldwide. The program provides lifeline seed funding, critical coaching, and continuous access to AIM-HI's valuable global network to address unmet medical needs for cancer patients.
Benefits include unique opportunities for women-led oncology companies to (1) apply for up to $1 million investment, (2) receive recognition, visibility, and introductions to cancer experts worldwide, and (3) be featured in the Award Ceremony for the 2023 Women's Venture Competition and network with key opinion leaders, business executives, investors, and fellow women entrepreneurs in the life science startup ecosystem.
Deadline: Wednesday, March 15, 2023
|
|
|
Notice of Special Interest (NOSI): Administrative Supplements for NCI Division of Cancer Biology (DCB) Research Programs
You may submit applications for this initiative using any of the 24 funding opportunity announcements (FOAs) listed on the website above or any reissues of these announcement through the expiration date of this notice.
Through this NOSI, current awardees of DCB-led programs can apply for supplemental funding to support collaborative research projects. DCB-led or DCB-co-led programs appropriate for this NOSI include the Acquired Resistance to Therapy Network (ARTNet), the Cancer Systems Biology Consortium (CSBC), the Cancer Tissue Engineering Collaborative (TEC), the Cellular Cancer Biology Imaging Research (CCBIR) program, the Metastasis Research Network (MetNet), the Onco-Aging Consortium (OAC), the Oncology Models Forum (OMF), the Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium (PSRC), the Patient-Derived Models of Cancer Program (PDMC), the Physical Sciences-Oncology Network (PS-ON), the Program on the Origins of Gastroesophageal Cancers, and the Translational and Basic Science Research in Early Lesions (TBEL) consortium.
Deadline: April 20, 2023
|
|
|
NOSI: Administrative Supplements to Examine the Effects of Digital Tools and Interventions on Patient-provider Communication across the Cancer Control Continuum
Applications for this NOSI must be submitted using the following opportunity or its subsequent reissued equivalent: PA-20-272.
This NCI NOSI encourages currently funded NCI extramural investigators to apply for administrative supplements to better understand the effects of digital health tools and interventions on patient-provider communication across the cancer control continuum, with the aim of developing an evidence base to inform future development, modification, and delivery of digital tools and/or interventions for effective cancer prevention and control.
Deadline: April 21, 2023
|
|
|
NOSI: Administrative Supplement to Support Health Policy Research in Cancer Prevention and Control
Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent: PA-20-272
This NOSI encourages currently funded NCI extramural investigators to apply for administrative supplements to support cancer-related policy research, which features empirical evaluation of policy or evaluation of policy implementation or dissemination methods.
Deadline: April 21, 2023
|
|
NOSI: Administrative Supplements to Conduct Systematic Evidence Reviews on the Clinical Utility of Cancer Site-specific Polygenic Risk Scores (PRS) for Cancer Risk Assessment
Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent: PA-20-272
This NOSI encourages currently funded NCI extramural investigators to apply for administrative supplements to (1) conduct systematic evidence reviews that assess the state of the science on the clinical utility of cancer site-specific polygenic risk scores for cancer risk assessment and (2) inform future trials and research directions for clinical translation and implementation.
Deadline: April 23, 2023
|
| NOSI: Research on the Etiology, Early Detection, Screening, and Prevention of Early-Onset Colorectal Cancer
This NOSI applies to due dates on or after January 5, 2023 and subsequent receipt dates through July 2, 2025. You may submit applications for this initiative using any of the 30 FOAs listed on the website below or any reissues of these announcement through the expiration date of this notice.
|
|
|
NOSI: Administrative Supplement to Support Global Cancer Stigma Research
Applications can be submitted on a rolling basis between January 16, 2023 and May 21, 2023 at 5:00 p.m. local time of applicant organization for FY 2023 funding. Applications for this initiative must be submitted using the following FOA or its subsequent reissued equivalent: PA-20-272
|
|
NOSI: Career Development Opportunities for Research within the Mission of the NCI Division of Cancer Prevention (DCP)
This NOSI applies to due dates on or after February 12, 2023, and subsequent receipt dates through November 13, 2024.
|
| NOSI: Technology Development for Cancer Control and Population Science Research.
This NOSI applies to due dates on or after March 1, 2023 and subsequent receipt dates through the expiration date of this notice.
|
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, and U2C Clinical Trial Optional)
Budgets may not exceed $150,000 in direct costs per year.
Deadline: March 1, 2023 and September 1, 2023
|
| Department of Defense (DoD) Ovarian Cancer, Investigator-Initiated Research Award
Amounts from $300K to $800K; pre-application required; due dates April 17 2023.
Deadline: July 21, 2023
|
| DoD Lung Cancer, Translational Research Award
Amounts from $375K to $1.2M; pre-application required; due dates May 2 and May 10 2023.
Deadline: August 3, 2023
|
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, and U2C Clinical Trial Optional)
Budgets may not exceed $150,000 in direct costs per year.
Deadline: March 1, 2023 and September 1, 2023
|
| NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
A budget for direct costs of up to $50,000 per year may be requested; maximum project period is 2 years.
Deadline: Standard NIH deadlines apply
|
| Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
The combined budget for direct costs for the 2-year maximum project period may not exceed $275,000; no more than $200,000 may be requested in any single year.
Deadline: Standard NIH deadlines apply
|
|
|
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Budgets are not limited but must reflect the actual needs of the proposed project; maximum project period is 5 years.
Deadline: Standard NIH deadlines apply
|
| Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Budgets are limited to $600,000 direct costs (excluding consortium F&A) per year; maximum project period is 5 years.
Deadline: Standard NIH deadlines apply
|
| NOSI: Adaptive Biomaterials for Cancer Biology
This NOSI invites applications that propose the development of advanced biomaterials for use in fundamental cancer biology research and proposals incorporating the novel application of advanced biomaterials to address cancer biology research questions.
Deadline: Standard NIH deadlines apply
|
|
|
POSTDOCTORAL FUNDING OPPORTUNITIES
|
|
|
MCC Cancer Therapeutics Training (CT2) Program: Open Positions Available
PIs: Dr. Michael Bouvet and Dr. Dwayne Stupack
Description: The goal of the CT2 Program is to train the next generation of leaders in the field of cancer drug and diagnostics development. The CT2 Program is open to both M.D.s and Ph.D.s and provides an intensive 2-year period of research and training in the development of novel cancer therapeutics or diagnostics at MCC. Trainees not only execute a research program under the direction of a member of the faculty of this NCI-Designated Comprehensive Cancer Center, but also participate in coursework, seminars, and lectures. The research may be basic, translational, or clinical, yet all trainees will become versed in each major phase of the drug development process. Graduates of the program are prepared to transition to leadership roles in cancer therapeutics development in either an academic or commercial environment.
Salary/Stipend Information: NIH stipend scale
Application Procedure, Documents, and Requirements
See website for more details about CT2 program: WEBSITE
|
- Complete CT2 program application (form available to download from the website above)
- Curriculum vitae
- One-page personal statement
- Proof of U.S. citizenship or permanent resident status
- Three letters of recommendation (one from an identified mentor)
- Ph.D. or M.D. degree
|
For more information or to apply, please contact
Amy Spilkin, Ph.D. at aspilkin@health.ucsd.edu
Deadline: March 15, 2022
|
|
|
American Association for the Study of Liver Diseases (AASLD), Harold Amos Medical Faculty Development Program (AMFDP) Award Opportunity
Applications available: February 8, 2023
Application deadline: March 16, 2023
As part of AASLD's efforts to advance our shared goal of cultivating the next generation of academic leaders, AASLD has partnered with the AMFDP of the Robert Wood Johnson Foundation (RWJF). The program has been designed to increase the number of scholars from historically marginalized groups in the field of hepatology with academic and research appointments. The AASLD-AMFDP Award offers 4 years of postdoctoral research support to historically disadvantaged physicians who are committed to developing careers in academic medicine and serving as role models for students and faculty of similar backgrounds.
About the AASLD-AMFDP (Harold Amos Award)
For over 20 years, RWJF has worked to increase the representation of minority scholars in academic medicine through its AMFDP, which was created to assist faculty from historically disadvantaged backgrounds to achieve senior rank in academic medicine. The AMFDP is named after Harold Amos, Ph.D., who was the first African-American to chair a department (now the Department of Microbiology and Medical Genetics) at Harvard Medical School.
The AASLD Governing Board recently approved support for the program to strengthen its commitment to diversity, equity, and inclusion efforts in hepatology. Through the program, AASLD is committed to funding one AMFDP hepatology scholar for 4 years. The selected scholar (1) is expected to spend at least 70 percent of his or her time on research activities, in association with a senior faculty member located at an academic medical center and (2) will receive an annual stipend of up to $75,000, complemented by a $30,000 annual grant toward support of research activities.
Program Mentorship
The selected awardee will be assigned a National Advisory Committee mentor, following an application review and an in-person interview, who will follow his or her progress throughout the award term and provide additional guidance.
The selected cohort will meet for mentoring and leadership training.
Eligibility Requirements
To be eligible for this award, the applicant must meet the following requirements:
|
- Physician or nurse from a historically disadvantaged background (ethnic, financial, or educational) who has excelled in his or her education
- U.S. citizen or permanent resident at the time of the application deadline
- Completing or have completed formal clinical training
- Prepared to devote 4 consecutive years to research
-
Committed to pursuing an academic career and improving the health status of the underserved, decreasing health disparities, or serving as a role model for students and faculty from historically disadvantaged backgrounds.
|
Application Process
To view detailed application requirements and begin the application process, please visit the AMFDP website.
|
|
|
Postdoctoral Positions in Cancer Research
The laboratory of Dr. Thomas Kipps at MCC is seeking highly qualified and motivated postdoctoral fellows (scientists) to participate in state-of-the-art translational cancer research projects that investigate the genetics and immunology of cancer development and the generation of novel pharmacologic cancer therapeutics.
The Kipps lab specializes in novel therapeutics for patients with leukemia and solid tumors—for example, the function of onco-embryonic antigens, such as ROR1, which are selectively expressed by tumor cells and contribute to malignant behavior. This involves the development and testing of novel agents that can target such antigens and/or their associated signaling pathways that contribute to the survival, growth, metastatic potential, and/or cancer stemness of neoplastic cells, even in the setting of conventional anti-cancer therapy. This research can result in the development of more-effective therapies for patients with cancer.
Applicants for these postdoctoral positions must hold a Ph.D., possess strong analytical skills and proficiency in oral and written scientific presentations, and exhibit a demonstrated commitment to a career in cancer research. These postdoctoral positions are offered preferably to applicants who have recently received a Ph.D. or possess 3 years or less of post graduate education.
If interested, then submit a cover letter, curriculum vitae, statement of research interests, and the names and contact information of three reference to Dr. Laura Rassenti at lrassenti@ucsd.edu.
Dr. Laura Rassenti
Center for Novel Therapeutics
9310 Athena Circle
La Jolla, CA 92037-0809
858-822-5989
|
|
|
SITC Advances in Cancer Immunotherapy: A Focus on Lung Cancers
Thursday, April 6, 2023 from 12:00 p.m. to 4:00 p.m.
San Diego and Virtual
Free for healthcare professionals, students, patients, and patient advocates, this Advances in Cancer Immunotherapy program is CME-, CNE-, CPE- and MOC-certified and will be presented by leading authorities in tumor immunology and cancer immunotherapy. The program will provide the latest updates in immunotherapy for lung cancers and address practical applications, immune-related adverse events, and future trends.
|
|
|
Structural and Functional Genomics (SFG) Program Retreat
Friday, May 5, 2023
MCC Goldberg Auditorium and Lobby
Breakfast and lunch will be provided.
|
|
|
Joseph Califano, M.D.
Director, MCC
Director, Gleiberman Head & Neck Cancer Center
Professor, Department of Otolaryngology/Head & Neck Surgery UCSD, School of Medicine
Co-Leader, MCC, SFG Program
|
| Jill P. Mesirov, Ph.D.
Associate Vice Chancellor for Computational Health Sciences Professor, Department of Medicine
UCSD, School of Medicine Co-Leader, MCC, SFG Program
|
|
|
Big Data Training for Cancer Research—BigCare 2023 Summer Workshop
Friday, May 19, 2023 to Sunday, May 28, 2023
Purdue University
West Lafayette, Indiana
There is no cost for registration or tuition for this workshop, which will be held on-site at Purdue University. Moreover, there will be no cost for food or lodging, and travel scholarships will be available for a limited number of participants. Please visit the Purdue University Website for updates.
|
|
|
Newly Opened Clinical Trials
|
|
|
TMPS-101: A Single-Arm Phase II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients With PALB2 Mutations
PI: Kato, S
NCT: NCT05169437
|
| | |
|
GU20-436: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations (NePtune)
PI: McKay, R
NCT: NCT05498272
|
| | |
|
c20-256: CANOPY: Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer
PI: McKay, R
NCT: NCT05502315
|
| | |
|
NCI 10000048: A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer
PI: McKay, R
NCT: NCT04706663
|
| | |
|
GS-US-558-5915: A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
PI: Asimakopoulos, F
NCT: NCT04892446
|
| | |
|
10505: A Phase 1/2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma
PI: Piccioni, D
NCT: NCT05432804
|
| | |
|
SHARED RESOURCE SPOTLIGHT
|
|
|
MCC Biobehavioral Shared Resource (BBSR)
The goal of the BBSR is to enhance the feasibility and success of MCC investigators studying not only lifestyle behaviors and effect of interventions, but also biological indicators of cancer outcome, to reduce cancer risk and increase survival following the diagnosis of cancer. The BBSR provides expertise and guidance in developing and operationalizing behavioral research for MCC members who either do not have expertise in these areas or who have limited resources to use high-quality, science-based methodology without the context and efficiency of a consolidated service core.
The BBSR provides the following services:
|
-
Biological indicators assessment, which includes development of biological specimen processing protocols plus direct services for sample collection (e.g., phlebotomy) and processing (e.g., DNA and RNA extraction and small scale genotyping), instrument use (e.g., QiaCube), and laboratory analysis conducted in-house or by outside laboratories.
-
Behavioral assessment (e.g., dietary intake, physical activity, and body composition), which includes protocol development plus direct services (e.g., providing devices and training, conducting dietary recalls and questionnaires, and processing data).
-
Behavioral intervention services, which include guidance on design and content for weight loss, diet and physical activity interventions, protocol development, training, and guidance with new communication modalities.
|
The BBSR collaborates with the UCSD Exercise and Physical Activity Resource Center (EPARC), which facilitates the use of subsidized, accessible services relating to physical activity, fitness, strength, and body composition.
BBSR laboratory instrumentation and methodologies enable analysis of nutrients and dietary biomarkers in biological samples that are not generally available through clinical laboratories. Biological samples may include blood, urine, saliva, cell culture media, products, and formulations.
The BBSR not only provides services to members of other NCI-Designated Comprehensive Cancer Centers, but also supports clinical research projects conducted by NCI-supported cooperative groups.
Contact BBSR for More Information
For laboratory biological indicators assessment and sample collection, email Brinda Rana, Ph.D. at bkrana@ucsd.edu.
For dietary intake assessment and intervention services, email Cheryl Rock, Ph.D., R.D. at clrock@ucsd.edu and Christine Zoumas, M.S., R.D. at czoumas@ucsd.edu.
For physical activity, fitness, strength, and body composition assessment, email David Wing, M.S. at dwing@eng.ucsd.edu.
|
|
|
-
Wu C, Rakhshandehroo T, Wettersten HI (STT), Campos A, von Schalscha T, Jain S, Yu Z, Tan J, Mose E, Childers BG, Lowy AM (STT), Weis SM, Cheresh DA (STT). Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumour initiation. Nat Cell Biol. 2023 FEB 01.
-
Shen W, Middleton MS, Cunha GM, Delgado TI, Wolfson T, Gamst A, Fowler KJ, Alazraki A, Trout AT, Ohliger MA, Shah SN, Bashir MR, Kleiner DE, Loomba R (CCP), Neuschwander-Tetri BA, Sanyal AJ, Zhou J, Sirlin CB (STT), Lavine JE. Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis. J Hepatol. 2023 FEB 01.
-
Crews LA (HEM), Ma W, Ladel L, Pham J, Balaian L, Steel SK, Mondala PK, Diep RH, Wu CN, Mason CN, van der Werf I, Oliver I, Reynoso E, Pineda G, Whisenant TC, Wentworth P, La Clair JJ, Jiang Q (HEM), Burkart MD, Jamieson CHM (HEM). Reversal of malignant ADAR1 splice isoform switching with Rebecsinib. Cell Stem Cell. 2023 FEB 14.
- Kastrinos F, Kupfer SS, Gupta S (CCP). Colorectal cancer risk assessment and precision approaches to screening: Brave new world or worlds apart? Gastroenterology. 2023 FEB 23.
|
|
|
To submit any announcements, funding opportunities, events, or other important items to this newsletter, please make use of the newsletter submission form that is linked below. In order to submit to our newsletter submission form, you must be logged into Google with your UC San Diego email account.
Please direct any questions that you may have to our Marketing and Communications Coordinator, Sarah Christie at sjchristie@health.ucsd.edu
|
|
|
|
Want to be highlighted in the MCC weekly newsletter or on the MCC website?
We want to know and share in all of our successes at MCC. To that end, we have created a pipeline for our members to share recent publications, awards, new appointments, and research highlights that you would like to see in our MCC weekly newsletter or on the MCC website. Please provide us with the data that we need to showcase your great work by completing the Member Survey linked below.
We sincerely thank you in advance for your time!
|
|
|
Moores Cancer Center (MCC) is not only one of only 52 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers in the nation, but also the only one providing multidisciplinary, research-driven detection, treatment, survivorship, and prevention of cancer in San Diego County. The current 480 MCC member scientists and clinicians hail from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University, and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities, and pre-cancer and cancer-risk research, MCC investigators address translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. Holding Comprehensive status since 2001, MCC was founded in 1977 by John Mendelsohn and received its NCI designation in 1978.
|
|
|
Department of Research Administration
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails. View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to sjchristie@ucsd.edu. To continue receiving our emails, add us to your address book.
|
|
|
|